Jennerex, Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international

AMSTERDAM, April 26, 2013 /PRNewswire/ -Regular exercise has been proven to reduce the chance of developing liver cancer in a world-first mice study that carries hope for patients at risk from hepatocellular carcinoma (HCC).(Logo

Genomic Health expands coverage with ductal carcinoma in situ (DCIS) diagnosis, effective May 8

Research and Markets has announced the addition of the "EpiCast Report: Non-Small Cell Lung Cancer - Epidemiology Forecast to 2022" report to their offering

AMSTERDAM, Netherlands, April 28 (UPI) -- Swiss researchers say patients at risk from hepatocellular carcinoma -- the most common form of liver cancer -- may reduce their risk by regular exercise

Isis Pharma announced the initiation of a phase Ib/IIa study on ISIS-STAT3

( European Association for the Study of the Liver ) New data from two clinical trials presented today at the International Liver Congress 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma and cholangiocarcinoma using diagnostic urine tests

REDWOOD CITY, Calif. and PHILADELPHIA, May 2, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) and the ECOG-ACRIN Cancer Research Group announced today that the Journal of the National Cancer Institute

SAN DIEGO -- Lpath, Inc. , the industry leader in bioactive lipid-targeted therapeutics,has initiated dosing in a Phase 2a single-arm trial where ASONEP(TM) is being investigated as a treatment for renal